Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress [Yahoo! Finance]
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its price target raised by analysts at HC Wainwright from $25.00 to $28.00. They now have a "buy" rating on the stock.
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]